These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23396856)

  • 1. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
    Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
    Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
    J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
    Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
    J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
    Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
    Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
    J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-receptor switch during HAART is independent of virological success.
    Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
    J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
    de Mendoza C; Rodriguez C; García F; Eiros JM; Ruíz L; Caballero E; Aguilera A; Leiva P; Colomina J; Gutierrez F; del Romero J; Aguero J; Soriano V;
    J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
    Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
    Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
    Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
    Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
    Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
    J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
    J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
    Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
    J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
    Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
    Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.